Immix Biopharma prices $125 million stock offering alongside NEXICART-2 data update

Immix Biopharma, Inc. priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, according to a prospectus supplement dated September 29, 2026. The public offering price totals $125,000,007, with underwriting discounts and commissions of $7,500,000, leaving proceeds before expenses of $117,500,007.¹ The company estimated net proceeds of approximately $117.1 million after deducting underwriting discounts, commissions and estimated offering expenses.¹ Immix said it intends to use the net proceeds for NXC-201 clinical development, working capital and general corporate purposes.¹ The offering was expected to close on or about September 30, 2026, subject to customary closing conditions.²

On the same date, September 29, 2026, the company also disclosed clinical data. Immix announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee.¹ Additionally, all twenty-five of the new relapsed/refractory AL Amyloidosis patients are either in CR or already MRD-negative, and to date, all patients achieving MRD-negativity reached CR within one year of treatment.¹ In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing the future CR rate up to 98% (44/45); no relapses have been observed to date for patients who reached CR or MRD-negativity, and no neurotoxicity or enterocolitis has been observed to date.¹

NEXICART-2 is a fully enrolled, 45-patient multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in patients with relapsed/refractory AL Amyloidosis, with a registrational design, and the final readout and BLA submission are planned in mid-2027.¹ NXC-201 has been awarded RMAT designation by the FDA, Orphan Drug Designation by both the FDA and European Commission in AL Amyloidosis, and, in January 2026, Breakthrough Therapy designation by the FDA for relapsed/refractory AL amyloidosis, though the company said none of the foregoing should be viewed as an indication of the likelihood of receiving regulatory approval.¹

After the offering, the company expects 83,079,249 shares outstanding.¹ J.P. Morgan is acting as sole book-running manager for the offering.² The stock trades on the Nasdaq Capital Market under the symbol IMMX.¹